Iran is pushing boundaries amid rising tensions in the Gulf, but President Trump has so far not been "compelled" to retaliate militarily, analysts say.World Politicsread more
The deal could be announced as soon as next week, according to the report.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The U.K. will find out who its next prime minister will be on Tuesday.Europe Politicsread more
UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
Acadia Pharmaceuticals fell more than 22 percent in after-hours trading Wednesday on news that its CEO is retiring.
The bio-pharmaceutical company announced Wednesday afternoon that Uli Hacksell retired as both its CEO and a member of its board of directors, effective immediately. Chief Financial Officer Steve Davis would take over as interim CEO, the company said.
Separately, Acadia announced Wednesday that it would change the timing of its planned New Drug Application (NDA) submission for Nuplazid to the second half of the year. The company had originally planned to submit the application in the first quarter.
Acadia said it planned to hold a 5 p.m. ET conference call on Wednesday "to discuss its planned NDA submission and the management change."
Nuplazid is a drug potentially positioned "to be the only drug approved in the United States for psychosis associated with Parkinson's disease," according to Acadia's website.
Including Wednesday's after-hours trade, Acadia stock is up about 2,000 percent over past three years.
—Reuters contributed to this report.